MerTK mediates dexamethasone-induced suppression of antiviral CD8+ T cell immunity and exacerbates chronic LCMV infection
8 affiliations
- 1Laboratory of Experimental Medicine and Paediatrics, Faculty of Medicine and Health Sciences, University of Antwerp , ,
- 2Institute of Pathology, Section Immunopathology, Martin Luther University Halle-Wittenberg , ,
- 3Frazer Institute, The University of Queensland , , ,
- 4African Centre for Systematic Reviews and Knowledge Translation, Makerere University , ,
- 5Department of Cardiac Surgery, Uganda Heart Institute , ,
- 6The National Center for Radiation Research in Oncology , ,
- 7Medizinische Klinik und Poliklinik Zentrum für Innere Medizin , ,
- 8Department of Microbiology, Immunology and Infectious Diseases, College of Medicine and Health Sciences, Arabian Gulf University , ,
Abstract
Introduction: Glucocorticoids (GCs) such as dexamethasoneare widely used to treat allergies, autoimmune disorders, and chronic inflammatory conditions. However, their impact on antiviral immunity is complex and often contradictory. Clinically, dexamethasone can be beneficial in severe viral infections by suppressing excessive inflammation and limiting tissue injury. In contrast, during mild, early, or chronic infections, its immunosuppressive activity may delay viral clearance, promote viral replication or reactivation, and ultimately worsen disease outcomes. Reports describing both reduced and enhanced viral replication following GC treatment underscore the pleiotropic nature of GC action, yet the underlying mechanisms remain poorly understood.
Methods: We investigated the effect of dexamethasone during persistent LCMV infection in wild-type (Mertk+/+) and MerTK-deficient (Mertk–/–) mice (20-25g body weight). Animals were infected with 2 × 104 PFU of the LCMV Docile strain intravenously and randomly assigned to two intervention arms, receiving either PBS or dexamethasone (2.5mg/kg, dose adjusted according to body weight) intraperitoneally every 48 hours.On day 8 post-infection, blood was collected prior to euthanasia, after which spleen and liver samples were harvested for flow-cytometric analysis. Viral titres were subsequently quantified in the spleen, liver, kidney, lung, and lymph nodes.
Results: In Mertk+/+ mice, dexamethasone induced pronounced loss of CD8+ T cells and enhanced MerTK-dependent suppression of virus-specific CD8+ T cell responses, an effect largely absent in Mertk–/– animals. Functionally, dexamethasone substantially increases production of the anti-inflammatory cytokine IL-10 by macrophages and dendritic cells and elevates expression of the inhibitory checkpoint molecule PD-1 on LCMV-specific CD8+ T cells in Mertk+/+ mice. Moreover, expression of KLRG1, CD44, and CD127 on CD8+ T cells were substantially reduced, indicating impaired effector differentiation, whereas CD62L+ CD8+ T cells were upregulated, suggesting retention in a naïve or central-memory–like state. Together, these changes promoted functionally impaired CD8+ T cell phenotype, weakened LCMV-specific immunity, and facilitated viral dissemination across multiple organs examined. Genetic ablation of MerTK mitigated these immunosuppressive effects, resulting in significantly improved viral control.
Discussion: These findings demonstrate that the immunosuppressive effects of dexamethasone are critically dependent on the MerTK-mediated immunoregulatory axis. By identifying MerTK as a central node through which GCs reinforce inhibitory immune circuits, our study highlights MerTK as a potential target for future therapeutic intervention at the frontier of viral infections and inflammatory diseases. However, this therapeutic potential is currently supported solely by genetic loss-of-function evidence, and future studies employing pharmacological MerTK inhibition will be required to validate its efficacy and translational applicability.
Related
- Integrated in vivo and transcriptomic analyses of lethal Oropouche virus infection reveal suppression of pathogenic host responses by antiviral therapy
- Influenza A (H1N1)pdm infection exacerbates behavioral, cognitive, and synaptic impairments in 5xFAD mice
- A PVH-to-parabrachial BDNF circuit mediates non-aversive feeding suppression
- A queen odour mediates reproductive suppression in a eusocial mammal
- Antiviral mechanism of glycyrrhizic acid against BVDV: suppression of viral replication and immune regulation
BibTeX
@article{adomati2026mertk,
title = {{MerTK mediates dexamethasone-induced suppression of antiviral CD8+ T cell immunity and exacerbates chronic LCMV infection}},
author = {Tom Adomati and Thamer A. Hamdan and Barbara Seliger and Vikas Duhan and Jacqueline E. Akite and Herbert Ariaka and Hilal Bhat and Murtaza Ali and Lamin B. Cham},
journal = {Frontiers in cellular and infection microbiology},
year = {2026},
month = oct,
doi = {10.3389/fcimb.2026.1961552},
url = {https://europepmc.org/article/PMC/PMC13730832},
note = {CC BY},
}
RIS
TY - JOUR
TI - MerTK mediates dexamethasone-induced suppression of antiviral CD8+ T cell immunity and exacerbates chronic LCMV infection
AU - Tom Adomati
AU - Thamer A. Hamdan
AU - Barbara Seliger
AU - Vikas Duhan
AU - Jacqueline E. Akite
AU - Herbert Ariaka
AU - Hilal Bhat
AU - Murtaza Ali
AU - Lamin B. Cham
PY - 2026
DA - 2026/10/21
JO - Frontiers in cellular and infection microbiology
DO - 10.3389/fcimb.2026.1961552
UR - https://europepmc.org/article/PMC/PMC13730832
AB - Introduction: Glucocorticoids (GCs) such as dexamethasoneare widely used to treat allergies, autoimmune disorders, and chronic inflammatory conditions. However, their impact on antiviral immunity is complex and often contradictory. Clinically, dexamethasone can be beneficial in severe viral infections by suppressing excessive inflammation and limiting tissue injury. In contrast, during mild, early, or chronic infections, its immunosuppressive activity may delay viral clearance, promote viral replication or reactivation, and ultimately worsen disease outcomes. Reports describing both reduced and enhanced viral replication following GC treatment underscore the pleiotropic nature of GC action, yet the underlying mechanisms remain poorly understood. Methods: We investigated the effect of dexamethasone during persistent LCMV infection in wild-type (Mertk+/+) and MerTK-deficient (Mertk–/–) mice (20-25g body weight). Animals were infected with 2 × 104 PFU of the LCMV Docile strain intravenously and randomly assigned to two intervention arms, receiving either PBS or dexamethasone (2.5mg/kg, dose adjusted according to body weight) intraperitoneally every 48 hours.On day 8 post-infection, blood was collected prior to euthanasia, after which spleen and liver samples were harvested for flow-cytometric analysis. Viral titres were subsequently quantified in the spleen, liver, kidney, lung, and lymph nodes. Results: In Mertk+/+ mice, dexamethasone induced pronounced loss of CD8+ T cells and enhanced MerTK-dependent suppression of virus-specific CD8+ T cell responses, an effect largely absent in Mertk–/– animals. Functionally, dexamethasone substantially increases production of the anti-inflammatory cytokine IL-10 by macrophages and dendritic cells and elevates expression of the inhibitory checkpoint molecule PD-1 on LCMV-specific CD8+ T cells in Mertk+/+ mice. Moreover, expression of KLRG1, CD44, and CD127 on CD8+ T cells were substantially reduced, indicating impaired effector differentiation, whereas CD62L+ CD8+ T cells were upregulated, suggesting retention in a naïve or central-memory–like state. Together, these changes promoted functionally impaired CD8+ T cell phenotype, weakened LCMV-specific immunity, and facilitated viral dissemination across multiple organs examined. Genetic ablation of MerTK mitigated these immunosuppressive effects, resulting in significantly improved viral control. Discussion: These findings demonstrate that the immunosuppressive effects of dexamethasone are critically dependent on the MerTK-mediated immunoregulatory axis. By identifying MerTK as a central node through which GCs reinforce inhibitory immune circuits, our study highlights MerTK as a potential target for future therapeutic intervention at the frontier of viral infections and inflammatory diseases. However, this therapeutic potential is currently supported solely by genetic loss-of-function evidence, and future studies employing pharmacological MerTK inhibition will be required to validate its efficacy and translational applicability.
SN - 2235-2988
ER -